DHR · Danaher Corp /De/
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Oct 2, 2023; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Diluted Net Earnings Per Common Share (Non-GAAP) non-GAAP | $4 | Six-Month Period Ended June 26, 2026 | — |
| Core sales growth (non-GAAP) non-GAAP | 3% | Three-Month Period Ended June 26, 2026 vs. Comparable 2025 Perio | — |
| Core sales growth excluding respiratory testing (non-GAAP) non-GAAP | 4.5% | Three-Month Period Ended June 26, 2026 vs. Comparable 2025 Perio | — |
| Free cash flow (non-GAAP) non-GAAP | $2.35B | Six-Month Period Ended June 26, 2026 | — |
| Free cash flow to net earnings conversion ratio (non-GAAP) non-GAAP | 1.24 | Six-Month Period Ended June 26, 2026 | — |
| non-GAAP free cash flow non-GAAP | 1.3B | Q2 2026 | — |
|
|
|||
| Operating cash flow to net earnings conversion ratio (GAAP) | 1.5 | Six-Month Period Ended June 26, 2026 | — |
| Respiratory testing sales | $250M | Three-Month Period Ended June 26, 2026 | — |
| Core sales growth (decline) (non-GAAP) non-GAAP | 0.5% | Three-Month Period Ended March 27, 2026 vs. Comparable 2025 Peri | — |
| Core sales growth (non-GAAP) - Biotechnology non-GAAP | 7% | Three-Month Period Ended March 27, 2026 vs. Comparable 2025 Peri | — |
| Core sales growth (non-GAAP) - Diagnostics non-GAAP | -4% | Three-Month Period Ended March 27, 2026 vs. Comparable 2025 Peri | — |
| Core sales growth (non-GAAP) - Life Sciences non-GAAP | 0.5% | Three-Month Period Ended March 27, 2026 vs. Comparable 2025 Peri | — |
| Non-GAAP core revenue non-GAAP | 2.5% | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DHR
this stock
Danaher Corp /De/
|
$151.51B | -5.9% | +8.5% | 38.2 | 1.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$234.31B | +9.4% | +14.5% | 34.1 | 1.3% |
|
NTRA
Natera, Inc.
|
$48.75B | +47.7% | -2.8% | — | 3.0% |
|
A
Agilent Technologies, Inc.
|
$43.80B | +14.0% | +6.4% | 31.1 | 1.8% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.33B | -18.2% | +10.4% | 38.7 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Oct 2, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DHR | +1.8% | +9.6% | +6.6% | +10.5% | -5.9% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +2.2% | +4.6% | -5.8% | +7.9% | -18.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.